The Anaphylaxis Campaign, was awarded a GSK IMPACT Award at a ceremony on Thursday 15th May 2014. From over 400 charities nationwide who applied for GSK’s flagship UK community investment programme, the Anaphylaxis Campaign is one of only ten winners and stood out for the impact it has across the UK in improving awareness of severe allergy and potentially deadly allergic reactions.
The charity was set up 20 years ago by a group of parents affected by severe allergy including David Reading, a journalist whose teenage daughter died suddenly of anaphylaxis.
Lynne Regent, CEO of the Anaphylaxis Campaign, said: ’We are thrilled to have won this award. It’s a great recognition of the Campaign’s work and influence over the last 20 years helping people understand the severity of some allergies and how to manage the condition safely. We hope this award also allows more people to learn more about our organisation and the support we can provide to people living with this condition everyday.‘
The GSK IMPACT Awards, run in partnership with The King’s Fund and now in their seventeenth year, are seen as a mark of achievement in the healthcare charity sector. In addition to the £30,000 they receive in unrestricted funding, winning organisations are able to access training, development, and networking opportunities through a dedicated programme organised by The King’s Fund.
Lisa Weaks, Third Sector Programme Manager at The King’s Fund said: ‘The Anaphylaxis Campaign is an impressive independent organisation carrying out targeted activity that protects people with allergies in a particularly effective way. It is an influential organisation providing high quality information, and has developed innovative awareness raising campaigns. This award is well-earned.’
A judging panel of health and charity experts who chose the winners includes broadcast journalist Fiona Phillips; Professor Steve Field, Chief Inspector of Primary Care at the Care Quality Commission; Gilly Green, Head of UK Grants at Comic Relief; Sir Christopher Gent, Chair of GSK, and Sir Chris Kelly, Chair of The King’s Fund.